214 results match your criteria ivig infliximab

IVIG Compared to IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children.

Pediatrics 2021 Sep 22. Epub 2021 Sep 22.

Department of Pediatrics, Section of Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO.

View Article and Full-Text PDF
September 2021

Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.

Lancet Child Adolesc Health 2021 Dec 27;5(12):852-861. Epub 2021 Oct 27.

Biostatistics Research Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA; Maria Fareri Children's Hospital at Westchester Medical Center, New York Medical College, Valhalla, NY, USA.

Background: Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10-20% of patients have recrudescent fever as a sign of persistent inflammation and require additional treatment. We aimed to compare infliximab with a second infusion of IVIG for treatment of resistant Kawasaki disease.

Methods: In this multicentre comparative effectiveness trial, patients (aged 4 weeks to 17 years) with IVIG resistant Kawasaki disease and fever at least 36 h after completion of their first IVIG infusion were recruited from 30 hospitals across the USA. Read More

View Article and Full-Text PDF
December 2021

Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area.

Viruses 2021 10 7;13(10). Epub 2021 Oct 7.

Department of Pediatrics, Istituto di Ricovero e Cura a Carattere Scientifico St. Orsola Polyclinic, University of Bologna, 40138 Bologna, Italy.

SARS-CoV-2 infection in children can trigger cardiovascular manifestations potentially requiring an intensive treatment and defining a new entity named Multisystem Inflammatory Syndrome in Children (MIS-C), whose features partially overlap with Kawasaki Disease (KD). A cross-sectional study including all diagnoses of MIS-C and KD from April 2020 to May 2021 in our metropolitan area was conducted evaluating clinical, laboratory (including immunological response, cytokines, and markers of myocardial damage), and cardiac (coronary and non-coronary) features at onset of the diseases. Evolution of ventricular dysfunction, valve regurgitations, and coronary lesions was documented. Read More

View Article and Full-Text PDF
October 2021

Netherton Syndrome: Case Report and Review of the Literature.

Skin Appendage Disord 2021 Aug 15;7(5):346-350. Epub 2021 Jun 15.

Department of Dermatology, University Hospital "Dr. José E. González," Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Netherton syndrome (NS) is a rare genodermatosis with an autosomal recessive pattern of inheritance caused by pathogenic variants in the SPINK5 gene. It is characterized by a triad consisting of atopic diathesis, ichthyosis linearis circumflexa, and hair shaft abnormalities. Ichthyosis linearis circumflexa can be confused with atopic dermatitis leading to a delayed diagnosis. Read More

View Article and Full-Text PDF

IVIG Compared to IVIG Plus Infliximab in Multisystem Inflammatory Syndrome in Children.

Pediatrics 2021 Sep 21. Epub 2021 Sep 21.

Department of Pediatrics, Section of Infectious Diseases, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO;

View Article and Full-Text PDF
September 2021

Longitudinally extensive transverse myelitis as a sign of multisystem inflammatory syndrome following COVID-19 infection: A pediatric case report.

J Neuroimmunol 2021 11 28;360:577704. Epub 2021 Aug 28.

Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

COVID-19 infection can cause inflammatory reactions that could involve several organs. In the pediatric population, Multi-System Inflammatory Syndrome in Children (MIS-C) has been reported as one of the consequences of COVID-19. We report a unique pediatric COVID-19 patient with MIS-C, associated with paralysis of the extremities. Read More

View Article and Full-Text PDF
November 2021

Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms.

J Pediatr 2021 Aug 30. Epub 2021 Aug 30.

Division of Cardiology, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada.

Objective: To evaluate practice variation in pharmacologic management in the International Kawasaki Disease Registry (IKDR).

Study Design: Practice variation in intravenous immunoglobulin (IVIG) therapy, anti-inflammatory agents, statins, beta-blockers, antiplatelet therapy, and anticoagulation was described.

Results: We included 1627 patients from 30 IKDR centers with maximum coronary artery aneurysm (CAA) z scores 2. Read More

View Article and Full-Text PDF

Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.

J Pediatr 2021 Aug 27. Epub 2021 Aug 27.

Department of Cardiology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan. Electronic address:

Objective: To detect risk factors of coronary artery aneurysm (CAA) development in patients with Kawasaki disease determined to have a low risk for resistance to primary intravenous immunoglobulin (IVIG) treatment based on the Kobayashi score.

Study Design: This study included 1757 predicted IVIG responders from Prospective Observational study on STRAtified treatment with Immunoglobulin plus Steroid Efficacy for Kawasaki disease (Post RAISE), a large-scale, multicenter, prospective cohort study of Kawasaki disease in Japan. Predicted IVIG responders were defined as patients with Kawasaki disease with a Kobayashi score of <5, a predictive scoring system for IVIG resistance created in Japan. Read More

View Article and Full-Text PDF

The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis.

Transl Pediatr 2021 May;10(5):1294-1306

Department of Cardiology, Children's Hospital Capital Institute of Pediatrics, Beijing, China.

Background: Kawasaki disease (KD) is a self-limited illness that results in coronary artery aneurysms (CAAs) and threatens children's health and lives. The therapeutic effects of single intravenous immunoglobulin gamma (IVIG) infliximab (IFX) (with or without IVIG) in young children with KD remain unclear. Thus, we made a meta-analysis and systematic review, including all of the studies which have evaluated the effectiveness and safety of IFX and IVIG KD patients. Read More

View Article and Full-Text PDF

Combined Single Nucleotide Variants of and in a Child with Refractory Kawasaki Disease.

Children (Basel) 2021 May 21;8(6). Epub 2021 May 21.

Department of Pediatrics, Kansai Medical University, Osaka, 2-5-1 Shin-machi, Hirakata-shi, Osaka 573-1010, Japan.

Kawasaki disease (KD) is a systemic vasculitis with an unknown etiology affecting young children. Although intravenous immunoglobulin (IVIG) plus acetylsalicylic acid is effective in most cases, approximately 10-20% of patients do not respond to this therapy. An 8-month-old boy was admitted to a local hospital with the presumptive diagnosis of KD. Read More

View Article and Full-Text PDF

Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.

Front Endocrinol (Lausanne) 2021 16;12:654473. Epub 2021 Apr 16.

Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy.

Graves' disease (GD) is an organ-specific autoimmune disorder of the thyroid, which is characterized by circulating TSH-receptor (TSH-R) stimulating antibodies (TSAb), leading to hyperthyroidism. Graves' ophthalmopathy (GO) is one of GD extra-thyroidal manifestations associated with the presence of TSAb, and insulin-like growth factor-1 receptor (IGF-1R) autoantibodies, that interact with orbital fibroblasts. Cytokines are elevated in autoimmune (i. Read More

View Article and Full-Text PDF

Cyclosporine for refractory Kawasaki disease with psoriasiform eruption.

JAAD Case Rep 2021 Apr 17;10:89-91. Epub 2021 Feb 17.

Division of Pediatric Dermatology, Nationwide Children's Hospital and The Ohio State University College of Medicine, Columbus, Ohio.

View Article and Full-Text PDF

Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms.

Pediatr Rheumatol Online J 2021 Mar 17;19(1):31. Epub 2021 Mar 17.

Division of Immunology, Boston Children's Hospital, 300 Longwood Avenue, Fegan 6, Boston, MA, 02115, USA.

Background: Despite timely administration of IVIG, some patients with Kawasaki disease (KD) develop rapidly progressive or giant coronary artery aneurysms (CAA).

Case Presentation: We describe our experience using cyclophosphamide (CYC) for the treatment of such cases as well as a review of the literature on the use of CYC in KD. Through a retrospective chart review of our KD population, we identified ten children treated for KD with intravenous CYC (10 mg/kg/dose) for one or two doses. Read More

View Article and Full-Text PDF

Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.

Eur J Pharmacol 2021 May 27;899:173985. Epub 2021 Feb 27.

Department of Cardiology, Children's Hospital of Soochow University, Suzhou, 215003, China. Electronic address:

This meta-analysis evaluated the efficacy and safety of infliximab as initial therapy for patients with Kawasaki disease (KD) and intravenous immunoglobulin (IVIG) resistant KD. Studies of infliximab in KD, published between January 2004 and December 2019, were curated from PubMed, MEDLINE, and Cochrane Library. Data were analyzed using STATA Version 12. Read More

View Article and Full-Text PDF

Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.

Arch Iran Med 2021 Feb 1;24(2):139-143. Epub 2021 Feb 1.

Department of Internal Medicine, Firoozgar Medical and Educational Hospital, Iran University of Medical Sciences, Tehran, Iran.

Background: Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU).

Methods: In this observational research, we studied 104 intubated adult patients with severe COVID-19 infection (based on clinical symptoms, and radiographic or CT scan parameters) who were admitted to the ICU of a multispecialty hospital during March 2020 in Tehran, Iran. Read More

View Article and Full-Text PDF
February 2021

Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.

Circ Cardiovasc Qual Outcomes 2021 02 5;14(2):e007191. Epub 2021 Feb 5.

Department of Cardiology (K.M., M. Miura), Tokyo Metropolitan Children's Medical Center, Japan.

Background: Coronary artery abnormalities (CAAs) still occur in patients with Kawasaki disease receiving intensified treatment with corticosteroids. We aimed to determine the risk factors of CAA development and resistance to intensified treatment in Post RAISE (Prospective Observational Study on Stratified Treatment With Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease)-the largest prospective cohort of Kawasaki disease patients to date.

Methods: In Post RAISE, 2648 consecutive patients with Kawasaki disease were enrolled. Read More

View Article and Full-Text PDF
February 2021

Refractory Kawasaki Disease-a Challenge for the Pediatrician.

SN Compr Clin Med 2021 Jan 28:1-6. Epub 2021 Jan 28.

Queen Elizabeth Hospital, Bridgetown, Barbados.

Kawasaki disease (KD) is an acute, self-limiting febrile illness of childhood associated with vasculitis, mainly of the medium-sized arteries. The clinical significance and impact of this condition arise from its predilection for the coronary arteries. The criteria for classic Kawasaki disease are clearly defined, but many children present with atypical forms, and clinicians need to consider this possibility. Read More

View Article and Full-Text PDF
January 2021

SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment.

Eur J Pediatr 2021 May 16;180(5):1581-1591. Epub 2021 Jan 16.

Division of Infectious Diseases, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI, 48201, USA.

This study was conducted to assess the clinical spectrum, management, and outcome of SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C). We reviewed medical records of children with MIS-C diagnosis seen at the Children's Hospital of Michigan in Detroit between April and June 2020. Thirty-three children were identified including 22 who required critical care (group 1) and 11 with less intense inflammation (group 2). Read More

View Article and Full-Text PDF

Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.

J Immunother Cancer 2021 01;9(1)

Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA

Background: Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management and outcomes for patients treated with intravenous immunoglobulin (IVIG), infliximab, or the combination of IVIG and infliximab for steroid-refractory ICI-pneumonitis.

Methods: Patients with steroid-refractory ICI-pneumonitis were identified between January 2011 and January 2020 at a tertiary academic center. Read More

View Article and Full-Text PDF
January 2021

Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.

Clin Drug Investig 2021 Jan 20;41(1):77-88. Epub 2020 Dec 20.

The Shizuoka Kawasaki Disease Study Group, Shizuoka, Japan.

Background And Objectives: Intravenous immunoglobulin (IVIG) therapy for acute-stage Kawasaki disease (KD) is the first-line treatment for preventing the development of coronary artery aneurysms (CAA). Corticosteroids (prednisolone) and infliximab are often used in patients at a high risk of CAA or those with CAA at diagnosis; however, there are only a few reports of non-responders to corticosteroids as an adjuvant therapy or rescue alternative to IVIG. In this study, we compared the therapeutic effects of primary and secondary prednisolone with IVIG for KD. Read More

View Article and Full-Text PDF
January 2021

A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.

Hosp Pediatr 2021 01 8;11(1):88-93. Epub 2020 Dec 8.

Department of Pediatrics and.

Background And Objectives: In 10% to 20% of cases, Kawasaki disease is refractory to intravenous immunoglobulin (IVIg), an expensive medication under a national shortage. Data suggest that infliximab is a viable alternative to a second dose of IVIg, with similar efficacy and safety. We compared the cost of a second IVIg dose to that of infliximab in the treatment of refractory Kawasaki disease (rKD). Read More

View Article and Full-Text PDF
January 2021

Endometriosis with infertility: A comprehensive review on the role of immune deregulation and immunomodulation therapy.

Am J Reprod Immunol 2021 03 19;85(3):e13384. Epub 2020 Dec 19.

Sorbonne Université, AP-HP, Hôpital Saint-Antoine, service de Médecine Interne and Inflammation, Paris, France.

Background: Endometriosis is a multifactorial pathology dependent on intrinsic and extrinsic factors, but the immune deregulation seems to play a pivotal role. In endometriosis-associated infertility, this could raise the benefit of immunomodulatory strategies to improve the results of ART. In this review, we will describe (1) sera and peritoneal fluid cytokines and immune markers; (2) autoantibodies; and (3) immunomodulatory treatments in endometriosis with infertility. Read More

View Article and Full-Text PDF

Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome.

Case Rep Oncol 2020 Sep-Dec;13(3):1252-1257. Epub 2020 Oct 14.

Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

We here report on a 74-year-old man diagnosed with a pT3cN0 -mutated and mismatch repair-deficient adenocarcinoma in the colon ascendens and 3 liver metastases. After hemicolectomy, the patient received treatment with the PD-1 inhibitor pembrolizumab. Three weeks later (on day 22), laboratory tests showed leukocytosis and an increase in transaminases; immune checkpoint inhibitor (ICI)-induced hepatitis was suspected and prednisolone therapy was initiated. Read More

View Article and Full-Text PDF
October 2020

Efficacy of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.

Exp Ther Med 2021 Jan 5;21(1):15. Epub 2020 Nov 5.

Department of Pediatrics, Soochow Children's Hospital, Suzhou, Jiangsu 215000, P.R. China.

The present study aimed to review the relevant studies in order to determine the efficacy of infliximab (IFX) in the treatment of Kawasaki disease (KD). The relevant studies were retrieved using the PubMed, Cochrane and Embase databases. Key sources in the literature were reviewed; all articles published by July 2019 were considered for inclusion. Read More

View Article and Full-Text PDF
January 2021

Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.

Rheumatology (Oxford) 2021 07;60(7):3413-3419

Pediatric Allergy Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Objectives: To carry out a review of clinical characteristics, laboratory profiles, management and outcomes of patients with Kawasaki disease (KD) and macrophage activation syndrome (MAS).

Methods: Medical records of patients treated for KD and MAS between January 1994 and December 2019 were reviewed. Patient demographics, clinical signs, laboratory values, coronary artery abnormalities, treatments and outcomes of patients with KD and MAS were recorded. Read More

View Article and Full-Text PDF

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist.

Rheumatology (Oxford) 2021 02;60(2):911-917

Department of Paediatric Rheumatology, London, UK.

Objectives: The objectives of this study were (i) to describe the clinical presentation, treatment and outcome of paediatric inflammatory multisystem syndrome temporally related to Sars-CoV-2 (PIMS-TS) in children; (ii) to propose a framework to guide multidisciplinary team (MDT) management; and (iii) to highlight the role of the paediatric rheumatologist in this context.

Methods: This study involved a retrospective case notes review of patients referred to a single specialist paediatric centre with suspected PIMS-TS, with a focus on clinical presentation, laboratory parameters, treatment, and outcome in the context of an MDT framework.

Results: Nineteen children of median age 9. Read More

View Article and Full-Text PDF
February 2021

Use of Adjunctive Therapy in Acute Kawasaki Disease in Latin America.

Front Pediatr 2020 15;8:442. Epub 2020 Sep 15.

University of California, San Diego, San Diego, CA, United States.

To characterize the use of adjunctive therapy in Kawasaki disease (KD) in Latin America. The study included 1,418 patients from the Latin American KD Network (REKAMLATINA) treated for KD between January 1, 2009, and May 31, 2017. Of these patients, 1,152 received only a single dose of IVIG, and 266 received additional treatment. Read More

View Article and Full-Text PDF
September 2020

Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [PIMS-TS] in a Patient Receiving Infliximab Therapy for Inflammatory Bowel Disease.

J Crohns Colitis 2021 Apr;15(4):687-691

Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, Uk.

Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [PIMS-TS] is a newly described condition. It has a spectrum of presentations proposed to occur as part of a post-infectious immune response. We report the first case of PIMS-TS in a child on established anti-tumour necrosis factor alpha [anti-TNFα] therapy; a 10 year-old girl with ulcerative colitis treated with infliximab. Read More

View Article and Full-Text PDF

Resolution of Giant Coronary Aneurisms in a Child With Refractory Kawasaki Disease Treated With Anakinra.

Front Pediatr 2020 7;8:195. Epub 2020 May 7.

Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Kawasaki disease (KD) is an acute, febrile illness of unknown etiology that mainly affects children under 5 years of age. intravenous immunoglobulin (IVIG), the standard treatment, has reduced coronary involvement to <5%. Patients who do not improve after an initial IVIG have a higher risk of developing coronary arteries aneurysms, and its optimal treatment remains controversial. Read More

View Article and Full-Text PDF